Aster Capital Management DIFC Ltd Has $640,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Aster Capital Management DIFC Ltd lifted its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 816.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,642 shares of the medical research company's stock after buying an additional 7,699 shares during the quarter. Aster Capital Management DIFC Ltd's holdings in Edwards Lifesciences were worth $640,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Harbor Capital Advisors Inc. raised its stake in shares of Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock worth $824,000 after buying an additional 273 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock valued at $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST grew its position in shares of Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock valued at $355,344,000 after purchasing an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $3,702,000. Finally, Avanza Fonder AB purchased a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $4,845,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 1.6 %

NYSE EW traded up $1.06 during trading hours on Friday, hitting $69.32. The company had a trading volume of 4,890,092 shares, compared to its average volume of 4,907,200. The firm's 50 day moving average is $71.32 and its 200 day moving average is $70.70. The company has a market capitalization of $40.75 billion, a price-to-earnings ratio of 9.95, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the transaction, the chief financial officer now owns 30,387 shares of the company's stock, valued at $2,153,526.69. The trade was a 27.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the transaction, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 62,853 shares of company stock worth $4,534,247 in the last 90 days. Corporate insiders own 1.29% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on EW. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Piper Sandler boosted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and raised their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Truist Financial reduced their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday. Finally, Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Hold" and an average price target of $78.55.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.